Reduced suicide risk during lithium maintenance treatment

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 9, 2000, Pages 97-104

  Tondo, Leonardo ^a,b,c   Baldessarini, Ross J ^a,b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

DRUG EFFICACY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; SOCIOECONOMICS; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; CLINICAL TRIALS; EUROPE; FEMALE; HUMANS; LITHIUM; MALE; PSYCHOTROPIC DRUGS; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE; UNITED STATES;

EID: 0033947858     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Jamison KR. Night Falls Fast. New York, NY: Alfred A. Knopf; 1999
2. Clark DC, Goebel-Fabbri AE. Lifetime risk of suicide in major affective disorders. In: Jacobs DG, ed. Harvard Medical School Guide to Assessment and Intervention in Suicide. San Francisco, Calif: Jossey-Bass; 1999: 270-286
3. Mosciki EK. Epidemiology of suicide. In: Jacobs DG, ed. Harvard Medical School Guide to Assessment and Intervention in Suicide. San Francisco, Calif: Jossey-Bass; 1999:40-51
4. Conwell Y, Henderson RE. Neuropsychiatry of suicide. In: Fogel BS. Schiffer RB, Rao SM, eds. Neuropsychiatry. Baltimore, Md: Williams & Wilkins; 1996:485-521
5. Hoyert DL, Kochanek KD, Murphy SL. National Vital Statistics Report. Hyattsville, Md: US Dept Health Human Services. National Center for Health Statistics; 1999. Publication 99-1120
6. Mäkinen IH, Washerman D. Suicide prevention and cultural resistance: stability in European countries' suicide ranking, 1970-1988. Ital J Suicidology 1997;7:73-85
7. Rosito M, Corfiatti L. D'Introno N, et al. Il suicidio adolescenziale in Italia: 1887-1987. Ital J Suicidol 1993;1(suppl):43-48
8. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970;117:437-438
9. Roy A. Suicide. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 2. 5th ed. Baltimore, Md: Williams & Wilkins; 1989: 1414-1427
10. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
11. Angst J, Sellaro R. Angst F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract 1998;2:115-119
12. Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999;60(suppl 2):57-62
13. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997;170:205-227
14. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the US: results from the National Comorbidity Study. Arch Gen Psychiatry 1994;51:8-19
15. Bebbington P, Rarnana R. The epidemiology of bipolar disorder. Soc Psychiatry Psychiatr Epidemiol 1995;30:279-292
16. Baldessarini RJ, Jamison KR. Summary and conclusions: effects of medical interventions on suicidal behavior: J Clin Psychiatry 1999;60(suppl 2): 117-122
17. Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999;60(suppl2):63-69
18. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;3:458-466
19. McCombs JS, Nichol MB, Stimmel GL, et al. Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(suppl 6):60-69
20. Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992;85: 444-448
21. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:431-459
22. Baldessarini RJ, Tondo L, Suppes T, et al. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Shulman KI, Tohen M, Kutcher S, eds. Bipolar Disorder Through the Life-Cycle. New York, NY: John Wiley & Sons; 1996:299-338
23. Suominen KH, Isometsä E, Hendriksson MM, et al. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry 1998;155:1778-1780
24. Angst J, Stassen HH, Gross G, et al. Suicide in affective and schizoaffective disorders. In: Marneros A, Tsuang MT, eds. Affective and Schizoaffective Disorders. Berlin. Germany: Springer-Verlag; 1990:168-185
25. Gunnell D, Frankel S. Prevention of suicide: aspirations and evidence. BMJ 1994;308:1227-1233
26. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-219
27. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-419
28. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993;7:191-195
29. Tondo L, Jamison KR, Baldessarini RJ. Antisuicide effects of lithium. Ann NY Acad Sci 1997;836:339-351
30. Baldessarini RJ, Tondo L. Antisuicidal effect of lithium treatment in major mood disorders. In: Jacobs DG, ed. The Harvard Medical School Guide to Suicide Assessment and Intervention. San Francisco, Calif: Jossey-Bass; 1999:355-371
31. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Therapeutics 1996;3:492-496
32. Viguera AC. Baldessarini RJ, Hegarty JM, et al. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry 1997;54: 49-55
33. Viguera AC, Baldessarini RJ, Friedberg J. Risks of interrupting continuation or maintenance treatment with antidcprcssants in major depressive disorders. Harv Rev Psychiatry 1998;5:293-306
34. Baldessarini RJ, Tondo L. Effects of lithium treatment in bipolar disorders and post-treatment-discontinuation recurrence risk. Clin Drug Investigation 1998;15:337-351
35. Baldessarini RJ, Tondo L, Viguera AC. Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999;1:17-24
36. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993;3:186-212
37. Freemantle N, House A, Song F, et al. Prescribing selective serotonin re-uptake inhibitors as strategy for prevention of suicide. BMJ 1994;309: 249-253
38. Verkes RJ, Van der Mast RC, Hengeveld MW, et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 1998;155:543-547
39. Müller-Oerlinghausen B, Berghöfer A. Antidepressants and suicidal risk. J Clin Psychiatry 1999;60(suppl 2):94-99
40. Leon AC, Keller MB, Warshaw MG, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999;156:195-201
41. Malone KM. Pharmacotherapy of affectively ill suicidal patients. Psychiatr Clin North Am 1997;20:613-625
42. Rose RM, Burt RA, Clayton PJ, et al. Consensus development conference statement: electroconvulsive therapy. JAMA 1985;254:2103-2108
43. Salzman C. Treatment of the suicidal patient with psychotropic drugs and ECT. In: Jacobs DG, ed. The Harvard Medical School Guide to Suicide Assessment and Intervention. San Francisco, Calif: Jossey-Bass: 1999: 372-382
44. Avery D, Winokur G. The efficacy of electroconvulsive therapy and antidepressants in depression. Biol Psychiatry 1977;12:507-523
45. Metzger ED. ECT and suicide. In: Jacobs DG, ed. The Harvard Medical School Guide to Suicide Assessment and Intervention. San Francisco, Calif: Jossey-Bass; 1999:406-414
46. Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. J Clin Psychiatry 1999;60(suppl 2): 104-110
47. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995;5:5-13
48. Isacsson G, Holmgren P, Wasserman D, et al. Use of antidepressants among people committ ng suicide in Sweden. BMJ 1994;308:506-509
49. Isacsson G, Holmgren P, Druid H, et al. Psychotropics and suicide prevention: implications from toxicological screening of 5281 suicides in Sweden. Br J Psychiatry 1999;174:259-265
50. Marzuk PM, Tardiff K, Leon AC, et al. Use of prescription psychotropic drugs among suicide victims in New York City. Am J Psychiatry 1995;152: 1720-1725
51. Rihmer Z, Rutz W, Barsi J. Suicide rate, prevalence of diagnosed depression and prevalence of working physicians in Hungary. Acta Psychiatr Scand 1993;88:391-394
52. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210
53. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408
54. Ohberg A, Lonqvist J. Sarna S, et al. Trends and availability of suicide methods in Finland: proposals for restrictive measures. Br J Psychiatry 1995;166:35-43
55. Fawcett J. Profiles of completed suicides. In: Jacobs DG, ed. The Harvard Medical School Guide to Suicide Assessment and Prevention. San Francisco, Calif: Jossey-Bass; 1999:115-124
56. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium maintenance treatment: depression and mania in bipolar I and II disorders. Am J Psychiatry 1998; 155:638-645
57. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar manic-depressive disorders. Br J Psychiatry. In press
58. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disorders 2000;2:3-7
59. Crundwell JK. Lithium and its potential benefit in reducing increased mortality rates due to suicide. Lithium 1994;5:193-204
60. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998;59: 405-414
61. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60(suppl 2):77-84
62. Prien RF, Klett CJ, Caffey CM. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974;131:198-203
63. Bech P, Vendsborg PB, Rafaelsen O. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976;53:70-81
64. Kay DWK, Petterson U. Manic-depressive illness. Acta Psychiatr Scand Suppl 1977;269:55-60
65. Glen AIM, Dodd M, Hulme EB, et al. Mortality on lithium. Neuropsychobiology 1979;5:167-173
66. Venkoba-Rao A, Hariharasubramanian N, Parvathi-Devi S, et al. Lithium prophylaxis in affective disorder. Indian Psychiatry 1983;23:22-30
67. Lepkifker E, Horesh N, Floru S. Long-term lithium prophylaxis in recurrent unipolar depression. Acta Psychiatr Belg 1985;85:434-443
68. Jamison KR. Suicide and bipolar disorders. Ann N Y Acad Sci 1986;487: 301-315
69. Schou M, Weeke A. Did manic-depressive patients who committed suicide receive prophylactic or continuation treatment at the time? Br J Psychiatry 1988;153:324-327
70. Nilsson A, Axelsson R. Lithium discontinuers: clinical characteristics and outcome. Acta Psychiatr Scand 1990;82:433-438
71. Coppen A, Standish-Barry H, Bailey J, et al. Does lithium reduce mortality of recurrent mood disorders? J Affect Disord 1991;23:1-7
72. Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991;21:33-38
73. Modestin J, Schwartzenbach F. Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatr Scand 1992; 85:173-175
74. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25:261-270
75. Rihmer Z, Szanto K, Barsi J. Suicide prevention: fact or friction? Br J Psychiatry 1993;162:130-131
76. Coppen A. Depression as a lethal disease: prevention strategies. J Clin Psychiatry 1994;55(suppl 4):37-45
77. Felber W, Kyber A. Suizide und Parasuizide während und ausserhalb einer Lithium prophylaxe. In: Müller-Oerlinghausen B, Berghöfer A, eds. Ziele und Ergebnisse der Medikamentösen Prophylaxe Affektiver Psychosen. Stuttgart, Germany: G Thieme Verlag; 1994:53-59
78. Lenz G, Ahrens B, Denk E, et al. Mortalität nach Ausschneiden aus der Lithiumambulanz. In: Müller-Oerlinghausen B, Berghöfer A, eds. Ziele und Ergebnisse der Medicamentösen Prophylaxe Affektiver Psychosen. Stuttgart, Germany: G Thieme Verlag; 1994:49-52
79. Müller-Oerlinghausen B. Die "IGSLI" Studie zur Mortalität lithium behandelter Patienten mit affektiven Psychosen. In: Müller-Oerlinghausen B, Berghöfer A, eds: Ziele und Ergebnisse der Medikamentösen Prophylaxe Affektiver Psychosen. Stuttgart, Germany: G Thieme Verlag; 1994:35-39
80. Ahrens B, Müller-Oerlinghausen B, Schou M, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995;33:67-75
81. Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium: a complete population study in 362 patients. Pharmacopsychiatry 1995;28:8-13
82. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry 1996;29:103-107
83. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorders. Arch Gen Psychiatry. In press
84. Barraclough B, Bunch J, Nelson B. et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974;125:355-373
85. Poole AJ, James HD, Hughes WC. Treatment experiences in the lithium clinic at St. Thomas' Hospital. J Roy Soc Med 1978;71:890-894
86. Weeke A. Causes of death in manic-depressives. In: Schou M. Strömgren E, eds. Prevention and Treatment of Affective Disorders. New York, NY: Academic Press; 1979:289-299
87. Hanus K, Zalpetálek M. Suicidal activity of patients with affective disorders in the course of lithium prophylaxis. Ceskoslovenská Psychiatric 1984;80:97-100
88. Roy A. Suicide in recurrent affective disorder patients. Can J Psychiatry 1984;29:319-322
89. Norton B, Whalley LH. Mortality of a lithium treatment population. Br J Psychiatry 1984;145:277-282
90. Wickham EA, Reed FV. Lithium for the control of aggressive and self-mutilating behavior. Int Clin Psychopharmacol 1977;2:181-190
91. Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Lithium vs carbamazepine in the maintenance treatment of bipolar disorders: a randomized study. J Affect Disord 1997;43:151-161
92. Cappiello A, Sernyak MJ, Malison RT, et al. Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study. Biol Psychiatry 1997;42:1076-1078
93. Mann JJ, Arango V. Abnormalities of brain structure and function in mood disorders. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999: 385-393
94. Mann JJ, Oquendo M, Underwood MD, et al. The neurobiology of suicide risk: a review for the clinician. J Clin Psychiatry 1999;60(suppl 2): 7-11
95. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
96. Palmer DD, Henter ID, Wyatt RJ. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry 1999; 60(suppl 2):100-103
97. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-999
98. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-754
99. Keck P, Licht R. Antipsychotic medications in the treatment of mood disorders. In: Buckley PF, Waddington JL, eds. Schizophrenia and Mood Disorders. Boston, Mass: Butterworth Heinemann; 2000:199-211
100. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448-455
101. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
102. Suppes T, Baldessarini RJ, Faedda GL, et al. Discontinuing maintenance treatment in bipolar manic-depression: risks and implications. Harv Rev Psychiatry 1993;1:131-144
103. Baldessarini RJ, Tondo L, Faedda GL, et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-448
104. Baldessarini RJ, Tondo L, Floris G, et al. Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry 1997;154:548-550
105. Bocchetta A, Ardau R, Burrai C, et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998;18:384-389